Skip to main content

NCT00210496 - Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)

Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Topiramate
Product Name
TOPAMAX®
Therapeutic Area
Nervous System Diseases
Enrollment
406
% Female
N/A
% White
N/A
Product Class
Anticonvulsants
Sponsor Protocol Number
CAPSS-334
Data Partner
Johnson & Johnson
Condition Studied
Migraine Disorders
Mean/Median Age (Years)
N/A

Supporting Documentation

Clinical Study Report
Study Phase 
4
Additional Information: 

Please note: individual participant-level data are not available for this trial. Only the clinical study report is available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.